⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GILD News
Gilead Sciences Inc
Fraud Detection and Prevention (FDP) in BFSI Market worth $15.06 billion by 2031 - Exclusive Report by MarketsandMarkets™
prnewswire.com
MA
T
IBM
FIS
FISV
AXP
V
PYPL
COF
BK
BAC
JPM
WFC
C
MS
GS
SCHW
AXS
ALL
CB
PGR
TRV
UNM
MET
PRU
AIG
L
AIZ
SIGI
ENR
LNC
AGNC
IVZ
AMP
ICE
EQIX
AMZN
GOOGL
MSFT
NVDA
AMD
INTC
CSCO
ADBE
CRM
ORCL
SAP
ACN
GOOG
AMAT
MU
QCOM
TXN
INTU
ADP
PAYX
DXC
CTSH
INFY
WDC
SE
MELI
BABA
JD
NTES
PDD
BIDU
IQ
VIPS
XPEV
NIO
LI
LCID
RIVN
TSLA
GM
F
STLA
CHPT
BLNK
PLUG
FCEL
BE
RUN
SEDG
ENPH
CRSP
MRNA
BMY
PFE
JNJ
GILD
AMGN
BIIB
REGN
AZN
LLY
ABBV
XOM
CVX
SHEL
TTE
COP
EOG
APA
OXY
XNET
UPST
SOFI
HOOD
COIN
MP
EXAS
TDOC
ON
NXPI
MRVL
ALGN
IDXX
VRTX
SNPS
CDNS
MCHP
ADI
AVGO
LRCX
ASML
KLAC
TER
GPN
LXU
ACI
XPER
NICE
BCC
FEED
DV
ACTG to Make Three Presentations on HIV Cure and Aging with HIV at AIDS 2026
globenewswire.com
IBIO
GILD
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
RARE Drug Development Symposium Marks 10th Anniversary with Dedicated Pitch Sessions and The Theme and Call to Action to Align Advocates, Science and Industry
prnewswire.com
BIIB
REGN
GILD
BTE
BROS
BFLY
BCTX
BCRX
BTAI
ALRS
CAPR
CRIS
CYCN
EXAS
FATE
GNTX
HRMY
INCY
IONS
KODK
LAKE
LULU
MRNA
NBIX
NTRA
OCGN
ORGN
PGEN
PLRX
RARE
RGNX
RXRX
SAVA
SGMO
SNOW
SRPT
STEM
TGTX
TLSA
TXG
VRTX
ZETA
Transforming Bioprocessing for the Digital Age Takes Center Stage at the Bioprocessing Summit 2026
prnewswire.com
GILD
GSK
PFE
Secretome Therapeutics Expands Rare Disease Leadership Team
businesswire.com
SRPT
RPRX
PFE
BIIB
GILD
AMGN
ATRA
Gildan CHRO Brooke Ferguson and Vitalant Chief People Officer Manny Ocasio Join the Mainstage Lineup for McLean & Company Signature 2026 in Las Vegas
prnewswire.com
GILD
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
businesswire.com
GILD
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight
globenewswire.com
BMY
PFE
AMGN
NVS
MRK
LLY
GILD
AZN
TAK
JNJ
ABBV
CRSP
MOD
ARVN
ALK Inhibitors Market Set for Transformational Growth at a CAGR of 4% During the Forecast Period (2026-2036) Backed by Next-Generation Targeted Therapies| DelveInsight
prnewswire.com
PFE
MRK
LLY
AMGN
BMY
NVS
GILD
AZN
REGN
SNY
TEVA
IMUX